AstraZeneca to invest $360m in advanced manufacturing facility in Ireland
Investment will transform development and commercialisation of new medicinesAstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company’s global supply network is fit for future growth. The new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility. The $360m planned investment at